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Available online 29 June 2012Abstract Engraftment of human embryonic stem cell (hESC)-derived OPCs in animal models of demyelination results in
remyelination and clinical recovery, supporting the feasibility of cell replacement therapies in promoting repair of damaged
neural tissue. A critical gap in our understanding of the mechanisms associated with repair revolves around the effects of the
local microenvironment on transplanted cell survival. We have determined that treatment of human ESC-derived OPCs with
the pleiotropic cytokine IFN-γ promotes apoptosis that is associated with mitochondrial cytochrome c released into the cytosol
with subsequent caspase 3 activation. IFN-γ-induced apoptosis is mediated, in part, by secretion of the CXC chemokine ligand
10 (CXCL10) from IFN-γ-treated cells. Signaling through the chemokine receptor CXCR2 by the ligand CXCL1 functions in a tonic
manner by muting apoptosis and this is associated with reduced levels of cytosolic cytochrome c and impaired cleavage of
caspase 3. These findings support a role for both IFN-γ and CXCL10 in contributing to neuropathology by promoting OPC
apoptosis. In addition, these data suggest that hOPCs used for therapeutic treatment for human neurologic disease/damage
are susceptible to death through exposure to local inflammatory cytokines present within the inflammatory milieu.
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Oligodendrocyte progenitor cells (OPCs) are important in
mediating remyelination in response to demyelinating lesions
(Fancy et al., 2011; Cummings et al., 2005; Einstein et al., 2009;
Franklin and Ffrench-Constant, 2008). As such, OPCs represent
an attractive cell population for use in cell replacement
therapies to promote remyelination for treatment of human
demyelinating diseases (Ben-Hur and Goldman, 2008; Faulkner
and Keirstead, 2005; Martino et al., 2011; Potter et al., 2011;
Watson and Yeung, 2011) . High-purity OPCs generated from
Cytokine-induced apoptosis of human OPCs 209hESC and have been shown to initiate remyelination associated
with improved motor skills in animal models of demyelination
(Hatch et al., 2009b; Nistor et al., 2005; Sharp et al., 2010).
While promising, there is an extensive literature demonstrating
that cultured mouse OPCs are susceptible to apoptosis in
response to exposure to the pleiotropic cytokine IFN-γ
(Baerwald and Popko, 1998; Balabanov et al., 2007; Buntinx
et al., 2004a, 2004b; Horiuchi et al., 2006; Pouly et al., 2000;
Vartanian et al., 1995). This is relevant as many human
demyelinating diseases e.g. multiple sclerosis (MS) and spinal
cord injury (SCI) are associated with inflammation consisting of
activated lymphocytes secreting proinflammatory cytokines
including IFN-γ (Ankeny and Popovich, 2009; Rodriguez
Guerrero et al., 2012; Sospedra and Martin, 2005; Weiner,
2004). One potential reason for remyelination failure in many
human demyelinating diseases may be IFN-γ-induced death of
OPCs (Itoh et al., 2011; Pouly et al., 2000). Transplantation of
hESC-derived OPCs within an inflammatory microenvironment
suggests these cells would also be susceptible to IFN-γ-induced
apoptosis. The molecular mechanisms associated with regulat-
ing apoptosis as well as survival of hESC-OPCs have not been
well-characterized and represent an important gap in our
knowledge on the biology of these cells. Therefore, determining
if OPCs generated from hESCs are susceptible to IFN-γ-induced
death also represents an important and unanswered question.
We provide evidence that hESC-derived OPCs are suscep-
tible to IFN-γ-mediated apoptosis. Moreover, IFN-γ treat-
ment increases expression of CXCL10 mRNA transcripts and
protein and CXCL10 treatment induces apoptosis presumably
by signaling through the CXCR3 receptor that is expressed on
the surface of OPCs. Treatment with the chemokine CXCL1
inhibits IFN-γ or CXCL10-mediated OPC apoptosis that is
associated with muted cleavage of caspase 3 and increased
release of cytochrome c in the cytosol. CXCL1-mediated
protection occurs by signaling through the receptor CXCR2
as inclusion of a small molecule CXCR2-specific antagonist
prevents CXCL1-mediated protection from IFN-γ or
CXCL10-induced apoptosis and this was associated with
cleavage of caspase 3 and release of cytoplasmic cyto-
chrome c. These findings have implications for understand-
ing mechanisms associated with remyelination failure in MS
patients and also highlight the possibility that transplanted
hOPCs may be susceptible to IFN-γ-mediated apoptosis.Materials and methods
Cell culture and OPC differentiation
H7 human embryonic stem cells (hESC) were expanded on
matrigel coated flasks (BD Biosciences, San Diego, CA) and
fed hESC conditioned media supplemented with 10 ng/ml
basic FGF (Millipore, Temecula, CA) as previously described
(Nistor et al., 2005; Xu et al., 2001). Cells were fed daily and
passaged weekly when a 70% confluency was reached until
the necessary amounts of hESC cultures were needed for
differentiation. Cells were then differentiated according to
published protocols (Hatch et al., 2009a; Sharp et al., 2011).
Briefly, hESC colonies were dissociated and placed in low
adherent flasks with 50% hESC conditioned media and 50%
glial restrictive media (GRM) supplemented with 20 ng/ml
epidermal growth factor (EGF, Sigma Aldrich, CA) for thefirst day and EGF and 10 μM of retinoic acid (RA; Sigma
Aldrich, CA) for the second day. For an additional 7 days
floating spheres were fed 100% GRM supplemented with EGF
and RA. Cells were then exposed to GRM with 20 ng/ml EGF
for the remaining 32 days of the differentiation protocol. On
day 28 floating cells were plated onto matrigel coated flasks
and split after 1 week using TRPLE (Invitrogen, Carlsbad, CA)
and light trituration. On day 42 the cells were treated with
TRPLE again, spun down and prepared for experimental use.
A portion of the cells was plated into matrigel coated Nunc‐
permanox chamber slides (Fisher Scientific, Pittsburg, PA) at
a density of approximately 70,000 cells per well. Cells were
fed GRM supplemented with 20 ng/ml EGF for an additional
2 days and then fixed with 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA) in PBS for 10 min, washed
3 times, and analyzed by immunocytochemistry.
Immunocytochemical analyses
Fixed samples were exposed to 0.1% Triton‐X (Fisher
Scientific, Pittsburg, PA) for 15 min, washed in PBS 3 times
and then blocked with 10% normal goat serum (NGS, Jackson
ImmunoResearch, West Grove, PA) for 1 h at room temper-
ature. The following primary antibodies were applied to
cultures and incubated overnight at 4 °C: rabbit anti‐
Galactocerebroside (GalC, 1:300), rabbit anti‐NG2 (1:200),
rabbit anti‐Olig 1 (1:200), mouse anti‐nestin (1:200), mouse
anti‐O4 (1:200; all antibodies from Chemicon, Temecula,
CA), and rabbit anti‐GFAP (1:1,000; Dako, Carpinteria, CA).
Samples were washed in PBS, blocked with 10% NGS for
30 min at RT, and then Alexa fluorescent‐conjugated
secondary antibodies (goat anti‐rabbit Alexa 594 or goat
anti‐rabbit Alexa 488; 1:500 in PBS; Invitrogen, Carlsbad,
CA) were applied for 2 h at RT. All slides were then washed
in PBS, counterstained with Hoechst (1:1,000; Invitrogen,
Carlsbad, CA) for 2 min at RT and cover slip mounted using
Vectashield Mounting Medium (Vector Laboratories, Burlin-
game, CA). Negative controls were incubated in PBS instead
of primary antibodies. The percent of immunopositive cells
for each stain was determined by dividing the total number
of immunopositive cells by the total number of Hoechst
positive cells in each staining field. Results were obtained
from averaging three random fields within each staining
chamber as done previously (Hatch et al., 2009a).
Cytokine/chemokine treatment
hOPC cultures were treated with recombinant human
cytokines/chemokines including IFN‐γ (Cell Science, Canton
MA), CXCL10 (Peprotech, Rocky Hill, NJ), and CXCL1
(Peprotech). The CXCR2 antagonist SB265610 was purchased
from Tocris Bioscience (Minneapolis, MN).
Cell death assays
For MTT assay, cells were cultured in 96‐well plates with the
addition of treatments, or media as a control and cytotox-
icity was measured using the cell titer assay (Promega,
Madison, WI) according to manufacturer's instructions. The
formazan formed from MTT in actively metabolizing cells
was measured at an optical density of 570 nm and
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cell death relative to control. To assess apoptosis hOPCs
were plated on Matrigel coated chamber slides and treated
for a total of 6 days with culture medium changed every
2 days. At day six, cells were fixed with 4% paraformaldehyde
for 45 min at room temperature. hOPCs were permeabilized
and stained using TMR red, In Situ Cell Death Detection kit,
according to manufacturer's instructions (Roche, Indianapolis,
IN). Following apoptosis staining, slides were washed with PBS
and blocked using 10% NGS. Immunostaining was performed
using primary antibody, rabbit anti‐NG2 (1:200; Millipore)
and secondary antibody, goat anti‐rabbit Alexa 488 (1:500;
Invitrogen, Carlsbad, CA). Nuclear stain and slide preservation
were completed using Vectashield Mounting Mediumwith DAPI
(Vector Laboratories, Burlingame, CA). Immunofluorescence
was assessed using an Olympus Fluoview 1000 confocal
microscope and imaging analysis was carried out using Volocity
3D software (Improvision). For cell quantification, each treat-
ment was carried out in 2 chambers and three fields of each
chamber were examined. Results are expressed as mean±SD
of at least three different experiments in each time point, and
used for statistical analysis.
ELISA
Assessment of CXCL10, CXCL9, CXCL1 and CXCL2 in the
supernatants of hOPC cultures was performed following 48 h
of experimental treatment. Chemokines DuoSet sandwich
ELISA (R&D Systems, Minneapolis, MN, for CXCL1, CXCL9 and
CXCL10; Promokine Heidelberg, Germany for CXCL2) was
performed according to manufacturer specifications and
results are presented as pg/ml.
Quantitative real‐time PCR
Total RNA was extracted in Trizol (Invitrogen) and purified
from treated and control hOPC cultures using Purelink RNA
Mini Kit according to manufacturer's protocol (Invitrogen).
cDNA synthesis was performed using Superscript VILO cDNA
Synthesis Kit (Invitrogen). Real‐Time PCR analysis was
completed using a LightCycler 480 Instrument II (Roche).
Chemokine mRNA levels were assessed using human primers
specific for: CXCL1, CXCL2, CXCL10, and CXCL9 (Table 1).
Amplicon expression was normalized to human β‐actin
(Invitrogen). LightCycler 480 SYBR Green I Master (Roche)Table 1 Primers used for real-time quantitative PCR.
Gene name Accession number Dir
CXCL1 NM_001511.2 Fo
CXCL1 NM_001511.2 Re
CXCL2 NM_002089 Fo
CXCL2 NM_002089 Re
CXCL9 NM_002416 Fo
CXCL9 NM_002416 Re
CXCL10 NM_001565.2 Fo
CXCL10 NM_001565.2 Re
β-actin NM_001101.3 Fo
β-actin NM_001101.3 Rewas used in all reactions with the following assay conditions:
10 min initial denaturation at 95 °C, and 45 cycles of 30 s at
95 °C and 1 min at 60 °C. Data were analyzed using Light-
Cycler 480 software (Roche).Western blotting
For western blot analysis, hOPC cultures were treated for
6 days then lysed using RIPA buffer (50 mM Tris–HCl pH 7.4,
175 mM NaCl, 5 mM EDTA, 1% NP‐40, 0.1% SDS, 0.5% DOC)
supplemented in protease and phosphatase inhibitors (Roche).
Mitochondrial and cytosolic fractions were isolated from hOPC
cultures using ProteoExtract Cytosol/Mitochondria fraction-
ation kit (Calbiochem, Gibbstown, NJ) following the manufac-
turer's protocol. Cell lysates were processed as previously
described (Tirotta et al., 2011). Antibodies used in blotting
were: rabbit anti‐human cytochrome c (1:200), rabbit anti‐
human α‐tubulin (1:4,000) rabbit anti‐human total caspase 3
(1:1,000), rabbit anti‐human cleaved caspase 3 (1:1,000),
rabbit anti‐human PARP (1:1,000; Cell Signaling, MA), rabbit
anti‐prohibitin (1:1,000), rabbit anti‐human CXCR2 (1:500;
Abcam), rabbit anti‐human CXCR3 (1:500; Abcam) and mouse
monoclonal anti‐human actin (1:5,000; Millipore, MA). HRP
conjugated secondary antibodies were used for detection
(1:25,000; Jackson ImmunoResearch Laboratory, West Grove,
PA) and exposed to Supersignal West‐Femto chemilumines-
cent reagent (Pierce, Rockford, IL). For detection of CXCR3,
Western blotting was performed using an antibody raised
against the human CXCR3 peptide that is cross‐reactive to
mouse CXCR3. Western blotting analysis of protein samples
from CXCR3+/+ and CXCR3−/− mouse OPC cultures confirmed
specificity (not shown). In addition, inclusion of the immunizing
CXCR3 used to generate the CXCR3 antibody blocked detection
of CXCR3 in hOPC cultures validating the antibody specificity.
Similarly, the anti‐CXCR2 antibody used for detection of human
CXCR2 is cross‐reactive to mouse CXCR2. Inclusion of protein
samples isolated from CXCR2+/+ and CXCR2−/− mouse OPC
cultures confirmed specificity of this reagent (not shown).Statistics
All data is presented as average±SEM or SD as indicated
in the figure legends. Statistically significant differences
were assessed by either unpaired student t‐test or one‐wayection Sequence
rward 5′ AACCGAAGTCATAGCCACAC 3′
verse 5′ CCTCCCTTCTGGTCAGTTG 3′
rward 5′ AACCGAAGTCATAGCCACAC 3′
verse 5′ CTTCTGGTCAGTTGGATTTGC 3′
rward 5′ TGGTGTTCTTTTCCTCTTGGG 3′
verse 5′ AACAGCGACCCTTTCTCAC 3′
rward 5′ CCTTATCTTTCTGACTCTAAGTGGC 3′
verse 5′ ACGTGGACAAAATTGGCTTG 3′
rward 5′ AGAAAATCTGGCACCACACC 3′
verse 5′ AGAGGCGTACAGGGATAGCA 3′
Cytokine-induced apoptosis of human OPCs 211ANOVA, and p values less than 0.01 were considered
significant.
Results
Directed differentiation of hESCs generates
high‐purity OPCs
At day 42 of the OPC differentiation protocol, cells were
trypsinized and plated for immunocytochemical analysis.
Consistent with earlier studies (Nistor et al., 2005; Schaumburg
et al., 2008), there was enriched staining for the OPC markers
NG2 (Fig. 1A) and Olig 1 (Fig. 1B) with cells exhibiting char-
acteristic bipolar morphology. Quantification of NG2 and Olig 1
expression on cultured cells revealed N90% of cells were
dual-positive for both antigens. While Gal C was detected on
cultured cells (not shown), expression was relatively muted
compared to NG2; thus, we consider these to be OPC-enriched
cultures at a relatively young stage of differentiation. There
was no evidence of nestin or O4 (data not shown) positive
staining indicating that the cells were not under-differentiated
or too mature for experimentation, respectively. These
OPC-enriched cultures did contain cells expressing the
astrocyte marker GFAP (Fig. 1C). Notably, the GFAP-positive
cells detected at this stage of differentiation are relatively
immature astrocytes and not displaying the characteristic
branching morphology, which is typical at this point in the
differentiation process (Gage et al., 1998; Nistor et al., 2005;
Schaumburg et al., 2008). No SSEA-4 staining was observed
(not shown) indicating that the cultures did not contain
undifferentiated cells.
hESC-derived OPCs are susceptible to apoptosis in
response to treatment with IFN-γ
Previous studies have demonstrated mouse and human oligo-
dendroglia (Buntinx et al., 2004a, 2004b; Chew et al., 2005;
Pouly et al., 2000) are susceptible to IFN-γ-mediated apoptosis
through distinct mechanisms including endoplasmic stress and
increased cleavage of caspase 3 (Baerwald and Popko, 1998;
Balabanov et al., 2006; Lin et al., 2006; Lin and Popko, 2009).
To test if hOPCs are susceptible to IFN-γ-mediated death,A B
Figure 1 Cells are committed to an oligodendrocyte progenitor (OP
the differentiation protocol cells were immunopositive for common
negative for older oligodendrocyte marker O4 (not shown). Cultu
commitment of the cells to an OPC lineage and this is also evidenced
contain GFAP-positive cells (C) but these cells did not have branch
Representative images are shown, scale bar=50 μM.cultured cells were exposed to increasing concentrations of
recombinant human IFN-γ and cell death determined by MTT
assay following 6 days of culture. IFN-γ treatment resulted in a
dose-dependent increase in cell death with ~90% of cells dying
in response to treatment with 1000 U/ml of IFN-γ (Fig. 2A). To
gain insight into whether IFN-γ treatment induced apoptosis of
hOPCs, cultures were treated for 6 days with 100 U/ml, and
TUNEL staining was performed. Increased TUNEL staining was
observed in response to IFN-γ treatment as compared to con-
trol cultures with ~40% of TUNEL‐positive cells (Figs. 2B–D).
CXCL10 induces apoptosis of hOPCs
We have previously shown that one mechanism by which IFN-γ
contributes to apoptosis of mouse OPCs occurs through induc-
tion of the CXC chemokine ligand 10 (CXCL10) in OPC-enriched
cultures by signaling through the receptor CXCR3 (Tirotta et al.,
2011). Similarly, IFN-γ treatment of hOPCs resulted in increased
CXCL10 and CXCL9 gene expression, although CXCL10 tran-
scripts were dramatically increased in comparison to CXCL9
(Fig. 3A). Correspondingly, ELISA performed on supernatants of
IFN-γ-treated hOPCs confirmed qPCR results and demonstrated
a N3-fold increase in CXCL10 levels (15,600±1300 pg/ml) as
compared to CXCL9 (3900±1100 pg/ml) indicating differential
responses with regards to secretion of these chemokines
following IFN-γ exposure (Fig. 3B). Western blotting confirmed
that cultured hOPCs express the 70 kDa CXCR3 protein and
expression was not affected following exposure to either IFN-γ
or CXCL10 when compared to media-treated cultures (Fig. 3C).
Moreover, treatment of cultured hOPCs with exogenous human
recombinant CXCL10 resulted in a dose-dependent increase
in cell death (Fig. 3D) and cell death was associated with
elevated TUNEL staining (Fig. 3E).
CXCL1 restricts IFN-γ/CXCL10-mediated apoptosis
of hOPCs
CXCR2 is a chemokine receptor that recognizes and binds to the
ligands CXCL1 and CXCL2. We have previously shown that
CXCL1, but not CXCL2, functions in a tonic manner to protect
mouse OPCs from both IFN-γ and CXCL10-mediated cytotoxic-
ity (Tirotta et al., 2011). To determine if IFN-γ treatmentC
C) lineage at day 42 of the differentiation protocol. At the end of
oligodendrocyte progenitor markers NG2 (A) and Olig 1 (B) but
res were also negative for Nestin (not shown) confirming the
by characteristic bipolar morphology. The cultures did, however,
ed morphology, suggesting these cells are immature astrocytes.
Figure 2 IFN-γ-induced apoptosis of hOPCs. (A) Cell cultures were exposed to IFN-γ in increasing concentrations (10, 50, 100, 500,
and 1000 U/ml) and cell viability was measured at day 2, 4, and 6 following treatment by MTT assay and values are compared to the
media. Data is presented as the mean±SEM of two independent experiments performed in replicate wells per assay condition. Cell
death occurs in a dose-dependent manner with increasing concentrations of IFN-γ resulting in elevated death. Representative
confocal image of NG2-positive OPCs (green) treated with media alone (B) or IFN-γ 100 U/ml (C) and stained for TUNEL-reactivity
(red) as well as DAPI (blue nuclei) after 6 days of treatment; scale bar=30 μm. (D) Quantification of TUNEL-positive cells indicates a
significant (***pb0.0001) increase in TUNEL staining in IFN-γ-treated cultures compared to media after 6 days. Data are expressed as
mean percentages±SD of apoptotic nuclei, and are derived from a minimum of three independent experiments.
212 E. Tirotta et al.modulated expression of CXCR2 ligands, cultured cells were
treated and CXCL1 and CXCL2 expression at both mRNA and
protein levels determined by qPCR and ELISA, respectively.
IFN-γ did not result in a dramatic increase in either CXCL1 or
CXCL2 transcripts (Fig. 4A) or protein (Fig. 4B) compared to
media-treated cultures indicating that IFN-γ is not a potent
inducer of expression of these CXCR2 ligands in hOPCs. In
contrast, hOPCs treated with CXCL1 increased expression of
CXCL1 transcripts (Fig. 4A) and protein (Fig. 4B) while CXCL2
expression was only marginally affected. Western blotting
revealed that cultured hOPCs constitutively express the
~55 kDa CXCR2 and, similar to CXCR3, expression is not
affected in response to IFN-γ (Fig. 4C). Inclusion of CXCL1 to
hOPCs treatedwith IFN-γ resulted in protection from cell death
with an effect that was dose-dependent (Fig. 4D). Treatment
of hOPCs with CXCL1 alone did not negatively affect survival
and actually protected cells when used at higher concentra-
tions (Fig. 4D). Inclusion of CXCL1 protected both IFN-γ-and
CXCL10 treated hOPCs from apoptosis as determined by
TUNEL staining (Fig. 4E). We next tested if blocking CXCR2
would affect CXCL1-mediated protection from either IFN-γ or
CXCL10-induced apoptosis. The small molecule SB265610 is an
allosteric inverse agonist that has previously been shown to
specifically bind to CXCR2 and inhibit receptor activation
(Auten et al., 2001; Bradley et al., 2009; Salchow et al., 2010).
Inclusion of SB265610 (50 nM) resulted in a significant
reduction (pb0.001) in the ability of CXCL1 to protect against
either IFN-γ or CXCL10-mediated apoptosis (Fig. 4F). Addition
of SB265610 did not appreciably increase TUNEL staining
compared tomedia alone yet did increase TUNEL staining from
hOPCs treated with CXCL1 alone (Fig. 4F).IFN-γ/CXCL10 signaling evokes a mitochondrial-
mediated apoptotic pathway in cultured OPCs
In order to understand mechanisms associated both with
IFN-γ/CXCL10-mediated apoptosis, we performed experi-
ments to evaluate the release of the pro-apoptotic molecule
cytochrome c following treatment with either IFN-γ or
CXCL10. Following a 6-day incubation with IFN-γ or CXCL10,
there were elevated amounts of cytochrome c detected
within the cytosolic fractions (confirmed by the presence of
α-tubulin and lack of prohibitin) (Fig. 5A). In contrast,
cytochrome c (~14 kDa) is not detected in IFN-γ or CXCL10
cultures in which CXCL1 is included (Fig. 5A). We next
examined cell lysates from experimental cultures for the
presence of the active form of caspase-3 (17 KDa). As shown
in Fig. 5B, treatment of hOPCs with either IFN-γ or CXCL10
for 6 days revealed cleavage of caspase 3. Further, IFN-γ or
CXCL10 treatment of hOPCs resulted in cleavage of PARP
that was generated through caspase cleavage (Fig. 5B).
Further, CXCL1 treatment blocked cleavage of caspase 3 in
response to either IFN-γ or CXCL10 treatment (Fig. 5C).
These findings confirm that exposure of hOPCs to IFN-γ as
well as CXCL10 induces apoptosis and reveals insight into
mechanistic pathways resulting in cell death.
Discussion
Cultured mouse OPCs are highly sensitive to IFN-γ-mediated
apoptosis (Baerwald and Popko, 1998; Balabanov et al.,
2006, 2007; Buntinx et al., 2004b; Horiuchi et al., 2006; Lin
Figure 3 CXCL10 treatment induces hOPC apoptosis. (A) Total
RNA was isolated from hOPCs following 2 days of IFN-γ (100 U/ml)
treatment and analyzed by semi-quantitative real‐time PCR, for the
expression of CXCL10 and CXCL9 using sequence specific primers.
Treatment with IFN-γ resulted in elevated expression of mRNA
transcripts specific for CXCL10 compared to CXCL9. Values were
determined by fold increase in transcript levels compared to
media-treated cultures derived from two independent experiments
and expressed as average±SEM. (B) Secreted CXCL10 and CXCL9
protein levels in supernatant from hOPC cultures treated with IFN-γ
(100 U/ml – 48 h) were measured by ELISA. Results represent the
mean±SEM of three independent experiments carried out in
triplicate. (C) Representative Western blot analysis of hOPC
cultures after 2 days of treatment with either IFN-γ (100 U/ml),
or CXCL10 (30 ng/ml), or media alone, showing an immunoreactive
signal specific for human CXCR3 (70 kDa). Post-translational modifi-
cations or multidimers are factors affecting the size of CXCR3 which
was detected at a molecular weight of 70 KDa (Colvin et al., 2004;
Ehlert et al., 2004; Tirotta et al., 2011). (D) hOPC cultures were
incubated with increasing concentrations of human CXCL10 (0.1, 1,
10, 30, and 50 ng/ml) over a period of 6 days. Viable cells were
measured by MTT assay and results represent the percent increase
of the cell death compared to the media-treated controls. Data is
presented as mean±SEM of two independent experiments.
*pb0.01, **pb0.001, ***pb0.0001. (E) Treatment of OPC cultures
for 6 dayswith CXCL10 at 30 ng/ml resulted in a significant increase
(pb0.001) in TUNEL-positive cells when compared to cultures
receiving media only. Values are expressed as average±SD and data
was obtained three independent experiments.
Cytokine-induced apoptosis of human OPCs 213et al., 2006, 2008; Vartanian et al., 1995; Wang et al.,
2010). Supporting this are recent studies from our laboratory
that have shown that one mechanism by which IFN-γ
contributes to mouse OPC apoptosis is through induction ofthe chemokine CXCL10 that subsequently binds to the
receptor CXCR3 (Tirotta et al., 2011). This study also
indicated that IFN-γ/CXCL10-mediated apoptosis was asso-
ciated with cleavage of caspase 3 (Tirotta et al., 2011).
Signaling through the chemokine receptor CXCR2 blocks
mouse OPC apoptosis by muting caspase 3 cleavage and
increasing expression of Bcl-2 which helps protect against
apoptosis (Tirotta et al., 2011). The present study was
undertaken to ascertain if human OPCs were susceptible to
apoptosis in response to IFN-γ/CXCL10 treatment and also
determine if CXCR2 signaling elicited protection in a manner
similar to mouse OPCs. Our findings reported in this study
support and extend earlier findings and indicate that one
mechanism by which IFN-γ evokes apoptosis of hOPCs is
through a CXCL10-dependent mechanism. hOPC-mediated
apoptosis following treatment with either IFN-γ or CXCL10
was associated with the presence of cytosolic cytochrome c
and cleaved caspase 3. Importantly, signaling through CXCR2
protects hOPCs from both IFN-γ and CXCL10-mediated
apoptosis and is associated with impaired release of
cytochrome c and blocking the cleavage of caspase 3.
Therefore, these data show that hES-derived OPCs are
susceptible to apoptotic death in response to exposure of
proinflammatory molecules and that CXCR2 signaling exerts
a protective effect.
These data provide new insight into potential mechanisms
by which CXCL10 contributes to demyelinating diseases.
Early studies revealed that CXCL10 was produced in active
lesions in patients with the demyelinating disease MS
and CXCR3-positive T lymphocytes were enriched within the
cerebral spinal fluid and parenchyma suggesting that migra-
tion of pathogenic T lymphocytes into the CNS was controlled,
in part, by CXCL10 (Balashov et al., 1999; Liu et al., 2005;
Simpson et al., 2000; Sindern et al., 2002; Sorensen et al.,
1999, 2001, 2002). Supporting this notion were studies
from animal models of immune-mediated demyelination.
Therapeutic blocking of CXCL10 was reported to impede T
lymphocyte accumulation within the CNS (that corresponded
with reduced IFN-γ expression) resulting in improved clinical
outcome as well as reduced neuropathology in both EAE and a
model of viral-induced demyelination (Fife et al., 2001; Liu
et al., 2001; Stiles et al., 2006a, 2006b; Wojcik et al., 1996).
More recent studies indicate that the functional role of
CXCL10 as well as CXCR3 in models of autoimmune neuroin-
flammatory demyelinating diseases is more complex with
regards to lymphocyte trafficking and activation (Byrne et al.,
2009; Klein et al., 2004; Lacotte et al., 2009; Liu et al., 2005,
2006; Muller et al., 2007, 2010; Narumi et al., 2002).
Nonetheless, our findings argue that local expression of
CXCL10 within white matter tracts may contribute to demy-
elinating diseases through induction of damage/death specific
for cells of an oligodendrocyte lineage. This notion is sup-
ported by the demonstration that blocking of CXCL10 signaling
in mice persistently infected with the neurotropic JHM strain
of mouse hepatitis virus (JHMV) results in extensive remyeli-
nation suggesting that myelin-producing cells of the CNS are
protected (Liu et al., 2001). It is intriguing to speculate
that OPCs are more sensitive to IFN-γ/CXCL10 death as these
cells are considered critical during periods of remyelination
as well as earlier findings arguing that susceptibility to
IFN-γ-mediated death is dependent upon the developmental
stage of oligodendrocyte lineage cells (Baerwald and Popko,
Figure 4 CXCL1 signaling protects hOPC cultures from IFN-γ and CXCL10-mediated apoptosis. (A) Semi-quantitative real‐time PCR was
performed to evaluate CXCL1 and CXCL2 mRNA transcripts in response to treatment with either IFN-γ (100 U/ml) or CXCL1 (30 ng/ml).
Values represent the fold induction relative to themedia-treated cultures. (B) Supernatants from treated cultureswere collected at day 2
and CXCL1 and CXCL2 protein levels were measured by ELISA. Data are expressed as mean of values±SEM of three independent
experiments. (C) hOPC cultures were treated with either media or IFN-γ (100 U/ml) for 2 days at which point total protein were
extracted and CXCR2 (55 kDa) was detected by Western blotting. (D) MTT assay demonstrating that CXCL1 protected cells from
IFN-γ-mediated cell death in a dose-dependent manner while CXCL1 also increased survival of media-treated hOPCs. Data are expressed
as average±SEM of two independent experiments; ** for pb0.001, *** for pb0.0001. (E) Quantification of TUNEL staining revealed that
CXCL1 (30 ng/ml) protects OPCs from either IFN-γ or CXCL10 mediated apoptosis following a 6‐day incubation; *** p≤0.0001. (F)
Treatment with the CXCR2 antagonist SB265610 (50 nM) reduces CXCL1-mediated protection from either IFN-γ or CXCL10-mediated
apoptosis as determined by TUNEL staining following a 6‐day treatment; ***pb0.0001. Data are expressed as average±SD and represent
three independent experiments.
214 E. Tirotta et al.1998; Balabanov et al., 2007; Horiuchi et al., 2006). Studies
by Popko and colleagues (Lin et al., 2006, 2008) indicate
IFN-γ-induced OPC death is related to ER-related stress and
this has dramatic consequences on myelin formation. At this
time, it is unclear whether CXC10-mediated OPC death is tied
directly with the ER stress responses and this warrants further
attention. Undoubtedly, there are additional mechanisms
by which IFN-γ evokes OPC death that are independent of
CXCL10 as IFN-γ treatment promotes expression of numerous
other factors that may participate in damage/death.
The demonstration that CXCR2 signaling protects OPC
cultures from both IFN-γ and CXCL10-mediated apoptosis
provides potentially important insight into how oligoden-
drocyte lineage cells protect themselves from death during
chronic neuroinflammation. Importantly, these findings
support and extend earlier work from our laboratory showing
that blocking CXCR2 signaling in a model of viral-induced
demyelination resulted in delayed recovery in clinical disease
that was associated with increased demyelination associated
with apoptosis of both mature oligodendrocytes and OPCs
without affecting either neuroinflammation or CNS viral
burden (Hosking and Lane, 2010). Moreover, we have recently
determined that inclusion of CXCL1 functions in a tonic
manner to protect mouse OPCs from either IFN-γ or
CXCL10-induced apoptosis and this was associated with
impaired cleavage of caspase 3 (Tirotta et al., 2011).Our findings reveal insight into potentially important
mechanisms contributing to demyelinating disease including
MS. Specifically, these data reveal that IFN-γ evokes
apoptosis in human OPCs through CXCL10 signaling to
CXCR3. Therefore, chronic CXCL10 expression within the
CNS may not only attract activated CXCR3-expressing
lymphocytes but also contribute to OPC death/apoptosis.
CXCR3 expression has been detected on both immature and
mature oligodendrocytes and elevated expression was
observed in tissues from MS patients, thus highlighting the
possibility of responding to CXCL10 (Omari et al., 2005). As
OPCs are considered critical in promoting remyelination, a
decrease in numbers via IFN-γ/CXCL10 mediated death may
contribute to remyelination failure often observed in the
majority of MS patients (Franklin, 2002). These findings
highlight that therapeutic strategies targeting CXCL10 may
be beneficial in treating human demyelinating diseases
including MS. In addition, approaches designed to enhance
CXCR2 signaling on OPCs may potentiate the remyelination
potential of these cells as well as limit myelin loss. Finally,
the use of hOPCs for treating spinal cord injury has recently
been performed (www.geron.com) and these cells may be
used for therapeutic application of other human neurologic
diseases in which myelin production is disrupted. Given the
possibility of local inflammatory responses in which IFN-γ
may be present, the potential cytotoxic effects of IFN-γ
Figure 5 IFN-γ/CXCL10 signaling induces mitochondrial cyto-
chrome c release into the cytosol and cleavage of caspase 3 in hOPC
cultures. (A) hOPCs were treated for 6 days under indicated
experimental conditions and were harvested and fractionated to
separate mitochondria from cytosolic components at which point
expression of α-tubulin, prohibitin, and cytochrome c determined
by Western blotting. Representative staining reveals cytochrome c
is detected in hOPC cultures treatedwith either IFN-γ or CXCL10 yet
is absent following inclusion of CXCL1. (B) Representative Western
blot demonstrating cleavage of caspase 3 and PARP in response to
treatment of cultured hOPCswith either IFN-γ or CXCL10 for 6 days.
The addition of CXCL1 to cultures blocked cleavage of both caspase
3 and PARP.
Cytokine-induced apoptosis of human OPCs 215within the microenvironment on transplanted hOPCs should
be recognized when considering the long-term effects of
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